Summary
The inappropriate use of antibiotics has rapidly accelerated antibiotic resistance evolution in pathogens, rendering several existing antibiotics ineffective. However, many pharmaceutical companies have discontinued their antibiotic research programs. This is foremost due to the rapid spread of multi-drug resistant bacteria, which makes the commercial success of new antimicrobial drugs unpredictable. Antibiotic developers do not have a toolset to appropriately test antibiotic candidates for resistance evolution. Specifically, in the early phase of drug development, researchers typically identify numerous lead molecules with antimicrobial activities. It would be imperative to estimate the rate of resistance evolution at this early stage of development to all lead candidates in order to choose those that are the least prone to resistance evolution. The applicant and his team developed a technology, they term DIvERGE. It enables the exploration of resistance in a manner that is more comprehensive and effective than any other currently used approach. In a nutshell, DIvERGE finds resistance mutations in antibiotic resistance genes at an unprecedentedly comprehensive manner . DIvERGE offers a unique opportunity for pharmaceutical companies to identify antimicrobial agents with potentially longer clinical efficacy at an early stage of drug development. Thus, the goal is simple and bold – to identify antibiotics that are less prone to resistance development. Here the team aims to commercialise the technology.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: | https://cordis.europa.eu/project/id/862077 |
Start date: | 01-11-2019 |
End date: | 31-10-2021 |
Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
The inappropriate use of antibiotics has rapidly accelerated antibiotic resistance evolution in pathogens, rendering several existing antibiotics ineffective. However, many pharmaceutical companies have discontinued their antibiotic research programs. This is foremost due to the rapid spread of multi-drug resistant bacteria, which makes the commercial success of new antimicrobial drugs unpredictable. Antibiotic developers do not have a toolset to appropriately test antibiotic candidates for resistance evolution. Specifically, in the early phase of drug development, researchers typically identify numerous lead molecules with antimicrobial activities. It would be imperative to estimate the rate of resistance evolution at this early stage of development to all lead candidates in order to choose those that are the least prone to resistance evolution. The applicant and his team developed a technology, they term DIvERGE. It enables the exploration of resistance in a manner that is more comprehensive and effective than any other currently used approach. In a nutshell, DIvERGE finds resistance mutations in antibiotic resistance genes at an unprecedentedly comprehensive manner . DIvERGE offers a unique opportunity for pharmaceutical companies to identify antimicrobial agents with potentially longer clinical efficacy at an early stage of drug development. Thus, the goal is simple and bold – to identify antibiotics that are less prone to resistance development. Here the team aims to commercialise the technology.Status
CLOSEDCall topic
ERC-2019-POCUpdate Date
27-04-2024
Images
No images available.
Geographical location(s)